Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

@inproceedings{Smith2014SurvivalAH,
  title={Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis},
  author={Bruce D. Smith and Charles L Beach and Dalia Ali Mahmoud and Laura Weber and Henry J. Henk},
  booktitle={Experimental hematology & oncology},
  year={2014}
}
BACKGROUND This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. METHODS A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. RESULTS Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 3 Excerpts

Similar Papers

Loading similar papers…